Skip to main content

Advertisement

Table 1 Baseline characteristics of the study population by treatment group

From: A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

  Peripheral SpA Axial SpA
Nilotinib (n = 5) Placebo (n = 8) Nilotinib (n = 8) Placebo (n = 9)
Age, median (IQR) years 39.5 (37.4–52.3) 47.1 (31.8–60.4) 38.0 (36.1–42.4) 40.1 (34.5–46.7)
Disease duration, median (IQR) years 4.6 (1.0–9.4) 8.4 (4.4–11.5) 5.8 (1.8–15.3) 4.0 (1.6–12.7)
Number of men/women 3/2 4/4 7/1 6/3
Inflammatory back pain (history/presence), n (%) 0 (0.0) 3 (37.5) 8 (100.0) 9 (100.0)
Peripheral arthritis (history/presence), n (%) 5 (100.0) 8 (100.0) 3 (37.5) 3 (33.3)
Enthesitis (history/presence), n (%) 0 (0.0) 3 (37.5) 3 (37.5) 6 (66.7)
Dactylitis (history/presence), n (%) 1 (20.0) 0 (0.0) 0 (0.0) 0 (0.0)
Patient’s global assessment, median (IQR) mm 52.0 (42.5–64.5) 63.5 (50.8–82.5) 67.0 (49.8–70.8) 70.0 (59.5–86.0)
Physician’s global assessment, median (IQR) mm 46.0 (43.5–64.5) 55.5 (49.0–59.5) 56.5 (47.3–58.0) 55.0 (50.0–60.0)
66 Swollen joint count, median (IQR) 9.0 (3.0–17.5) 3.5 (1.0–8.0) NA NA
68 Tender joint count, median (IQR) 8.0 (0.5–19.5) 9.5 (3.5–11.8) NA NA
BASDAI, median (IQR) NA NA 5.9 (4.2–6.9) 5.4 (4.9–6.8)
CRP, median (IQR) mg/l 9.2 (0.6–29.5) 14.8 (3.0–51.7) 4.8 (3.2–5.4) 6.3 (2.6–15.2)
ESR, median (IQR) mm/h 7.0 (3.5–31.5) 10.5 (5.0–42.3) 8.5 (2.0–12.0) 16.0 (3.5–36.5)
Concomitant NSAIDs, n (%) 4 (80.0) 6 (75.0) 8 (100.0) 9 (100.0)
Concomitant corticosteroids, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Concomitant methotrexate, n (%) 2 (40.0) 4 (50.0) 2 (25.0) 0 (0.0)
Concomitant sulfasalazine, n (%) 2 (40.0) 0 (0.0) 1 (12.5) 0 (0.0)
Previous anti-TNF treatment, n (%) 1 (20.0) 2 (25.0) 2 (25.0) 2 (22.2)
  1. Significance of the comparisons is determined by Mann–Whitney U test for continuous variables and Fisher’s exact test for categorical variables. There were no significant differences between the nilotinib and placebo groups
  2. SpA spondyloarthritis; IQR interquartile range; BASDAI bath ankylosing spondylitis disease activity Index; CRP C-reactive protein; ESR erythrocyte sedimentation rate; NSAIDs non-steroidal anti-inflammatory drugs; TNF tumor necrosis factor; NA not applicable